期刊文献+

基于^(18)F-FDG PET VCAR有效预测淋巴瘤诊疗效能的最新进展

Recent advances of effective prediction of lymphoma diagnosis and therapeutic based on 18F-FDG PET VCAR
原文传递
导出
摘要 淋巴瘤是起源于身体不同部位以及具有多种病理亚型的血液系统恶性肿瘤。传统使用的评价指标为最大标准化摄取值,其反映肿瘤组织中的最大活性代谢程度,是目前临床研究应用最多的代谢参数。PET体积计算机辅助判读(VCAR)软件可对淋巴瘤病灶进行测量分析,自动计算病灶的代谢评估指标,包括瘦体标准化摄取值峰值、肿瘤代谢体积和病灶糖酵解总量等。但淋巴瘤病理亚型分类繁多,上述代谢评估参数对不同亚型淋巴瘤的诊断和疗效评估效率各不相同。因此,笔者对基于18F-氟脱氧葡萄糖PET VCAR软件有效预测淋巴瘤诊疗效能的最新进展进行综述。 Lymphoma is a malignant tumor of the hematological system that originates from different sites of the body and has a variety of pathological types.Maximum standardized uptake value,a traditionally used evaluation index,can reflect the maximum metabolic activity in tumor tissues,and which is the most widely studied metabolic parameter in clinical research at present.PET volume computed assisted reading(VCAR)software can measure and analyze the lymphoma lesions and automatically calculate the metabolic evaluation indexes of the lesions,including the peak SUV normalized by lean body mass,metabolic tumor volume,total lesion glycolysis,etc.There are many pathological subtypes of lymphoma,and the above metabolic evaluation parameters have different diagnosis and efficacy evaluation efficiency for different types of lymphoma.Therefore,the author intends to review recent advances in the effective prediction of the diagnostic and therapeutic effect of lymphoma based on the metabolic assessment of 18F-fluorodeoxyglucose PET VCAR software.
作者 苏玉林 王梓延 宋姝 朱高红 Su Yulin;Wang Ziyan;Song Shu;Zhu Gaohong(Department of Nuclear Medicine,the First Affiliated Hospital of Kunming Medical University,Kunming 650032,China)
出处 《国际放射医学核医学杂志》 2021年第3期187-191,共5页 International Journal of Radiation Medicine and Nuclear Medicine
基金 国家自然科学基金(81360223、81860313) 云南省高级医学领军人才项目(L-2017003) 昆明医科大学研究生创新基金(2019S114)。
关键词 淋巴瘤 氟脱氧葡萄糖F18 正电子发射断层显像术 肿瘤代谢体积 病灶糖酵解总量 体积计算机辅助判读 Lymphoma Fluorodeoxyglucose F18 Positron-emission tomography Metabolic tumor volume Total lesion glycolysis Volume computed assisted reading
  • 相关文献

参考文献9

二级参考文献38

  • 1李艳,马红霞,王瑞峰,张少娟,张卫善,段小艺,郭佑民.^(18)F-FDGPET/CT的SUV值与肺癌患者的临床特征、病理类型及肿瘤标记物的关系研究[J].中华临床医师杂志(电子版),2012,6(21):6881-6884. 被引量:9
  • 2董菲,克晓燕.侵袭性非霍奇金淋巴瘤治疗进展[J].中国实用内科杂志,2007,27(24):1894-1898. 被引量:1
  • 3Wahl RL,Jacene H, Kasamon Y, et al. From RECIST to PER- CIST:evolving considerations for PET response criteria in solid tumors[J]. J Nucl Meal,2009,50(Suppl 1) :122S.
  • 4Frings V, van Velden FH, Velasquez LM, et al. Repeatability of metabolically active tumor volume measurements with FDG PET/ CT in advanced gastrointestinal malignancies:a multicenter study [J]. Radiology,2014,273(2) :539.
  • 5Bhoil A,Singh B,Singh N,et al. Can 3'-deoxy-3'-(18)F-fluorothy- midine or 2"-deoxy-2"-(18)F-fluoro-d-glucose PET/CT better as- sess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor,in non-small lung cancer patients Pre- liminary results[J]. Hell J Nucl Med,2014,17(2) :90.
  • 6Yanagawa M,Tatsumi M,Miyata H,et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET re- sponse criteria in solid tumors versus response evaluation criteria in solid tumors[J]. J Nucl Med,2012,53(6) :872.
  • 7Ding Q,Cheng X, Yang L, et al. PET/CT evaluation of response to chemotherapy in non-smaU cell lung cancer: PET response cri- teria in solid tumors (PERCIST) versus response evaluation crite- ria in solid tumors (RECIST)[J]. J Thorac Dis,2014,6(6):677.
  • 8Tahari AK,Paidpally V,Chirindel A, et al. Two-time-point FDG PET/CT:liver SULmean repeatability[J]. AJR Am J Roentgen- ol,2015,204(2) :402.
  • 9Minn H, Zasadny KR, Quint LE, et al. Lung cancer: reproducibili- ty of quantitative measurements for evaluating 2-[F-18]-fluoro-2- deoxy-D-glucose uptake at PET [J]. Radiology, 1995, 196 ( 1 ) : 167.
  • 10Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET [J].J Nucl Meal,1999,40(11) :1771.

共引文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部